Pharmacology
background shadow background pic pharmacology

 

 

2005 Krebs Lecture

2005 Edwin G. Krebs Lectureship in Molecular Pharmacology

The Eighteenth Annual Edwin G. Krebs Lecture in Molecular Pharmacology
Sponsored by an endowment from Sterling Winthrop, Inc.

presents:
Facing Grand Challenges:Drug Discovery and Development in the 21st Century

by: Roger M. Perlmutter, M.D., Ph.D.
Executive Vice President for Research and Development,
Amgen, Inc.

Tuesday, May 10, 2005
4:00 PM, Room T-435 HSC

Dr. Roger M. Perlmutter is Executive Vice President for Research and Development at Amgen, Inc., the world's largest biotechnology company. A graduate of Reed College (Portland, Oregon), Dr. Perlmutter received his M.D. and Ph.D. degrees from Washington University (St. Louis) in 1979. Thereafter he pursued clinical training in internal medicine at the Massachusetts General Hospital and at the University of California at San Francisco. From 1981 to 1984 he was a Lecturer in the Division of Biology at the California Institute of Technology.

He joined the Departments of Medicine and Biochemistry and the Howard Hughes Medical Institute at the University of Washington (Seattle) in 1984, and in 1989 became Professor and founding Chairman of the Department of Immunology. During this period, Dr. Perlmutter focused his scientific efforts on the elucidation of signaling pathways governing lymphocyte development and activation. In an early series of studies in collaboration with Dr. Edwin Krebs, he discovered the lymphocyte-specific protein tyrosine kinase lck and defined its role in T cell activation and neoplastic transformation. Later work elucidated the roles of other protein tyrosine kinase in lymphocyte signaling. Altogether, Dr. Perlmutter's studies greatly enhanced our understanding of the role of protein tyrosine kinases in the control of lymphocyte function in immunity.

In 1997 he left the University of Washington to join Merck and Co., ultimately rising to the rank of Executive Vice President, Worldwide Basic and Preclinical Research. He left Merck in 2001 to join Amgen in California.

Dr. Perlmutter is a director of Stem Cells, Inc., a Trustee of Reed College, and Chairman of the Board of Directors of the Institute for Systems Biology, a not-for-profit research institute based in Seattle, Washington. He has been a member of numerous scientific advisory boards and journal editorial boards, and he is a current member of the editorial board of the Journal of Clinical Investigation. He has also served as Councilor, Vice President, and President of the American Association of Immunologists. He was elected as a Fellow of the American Academy of Arts and Sciences in 2000.